For optimal viewing of the AACI Update click here.
News from the Association of American Cancer InstitutesDecember 2016
The Association is dedicated to reducing the burden of cancer by enhancing the impact of the nation's leading academic cancer centers.
AACI Update is an e-newsletter for the cancer center directors and key contacts at AACI member institutions as well as individuals interested in the cancer center-related activities of AACI. AACI Update reports on the progress of AACI initiatives along with other AACI endeavors that benefit the cancer community and highlights important news and events at AACI member institutions.

AACI encourages member institutions to submit cancer center highlights to AACI Update. News briefs are linked to complete stories posted on individual cancer center websites. Please e-mail materials to aaciupdate@aaci-cancer.org. AACI reserves the right to decide whether or not materials are appropriate for inclusion.

To subscribe to AACI Update, please send an e-mail to aaciupdate@aaci-cancer.org with your name, title, and telephone number asking to be added to the AACI's distribution list. To unsubscribe, please send an email with "unsubscribe" in the subject line.

Headlines
AACI President Aims to Integrate Treatment Advances in Community
Stanton L. Gerson, MD, director of the Case Comprehensive Cancer Center and University Hospitals Seidman Cancer Center, in Cleveland, was installed as the new president of the Association of American Cancer Institutes during AACI's annual meeting in Chicago, held October 23-25.

At the meeting, Dr. Gerson launched his two-year term with a presentation outlining plans for his presidential initiative, which will address a major objective of the Obama Administration's Cancer Moonshot initiative: Promoting collaborations with researchers, doctors and patients to improve patient outcomes and health care value in the community. A message from Dr. Gerson providing details about the initiative is available here. more...

Libutti Named New Rutgers Cancer Institute of New Jersey Director
Aiming to further propel scientific discovery as well as augment and expand comprehensive cancer services for patients through collaborative efforts with Rutgers and RWJBarnabas Health, Steven K. Libutti, MD, FACS, has been named as the new Director of Rutgers Cancer Institute of New Jersey and will serve as Vice Chancellor for Cancer Programs for Rutgers Biomedical and Health Sciences at Rutgers University. When he takes on his new roles in early 2017, Dr. Libutti will be the third permanent director in the 25-year history of the cancer institute. more...
AACI Commends House Passage of Revised 21st Century Cures Act
By a roll call vote of 392-26, the U.S. House of Representatives on November 30 passed a revised version of the 21st Century Cures Act, which provides $1.8 billion for cancer research. The bipartisan bill is headed to the Senate for a final vote. AACI leaders sent a letter to House and Senate leadership the day before the vote, asking that Congress complete work on the 21st Century Cures Act before the 114th Congress concludes.

"The nation's cancer centers applaud the bipartisan work that led to the passage of the 21st Century Cures Act in the House," said AACI Executive Director Barbara Duffy Stewart. "This bill is the most significant piece of legislation for patients fighting cancer in the 21st Century and ensures that advances in cancer prevention, diagnosis, treatment and care are within reach like never before." more...

AACI Update Winter Break
AACI Update will not be published in January. Many thanks to all of AACI's member centers that have submitted press releases and announcements throughout the year. Submission guidelines for AACI Update are available here.

The next AACI Update is scheduled for publication on February 1, 2017. Please keep the good news coming! more...

News from the Centers
Awards & Honors
Kirk, McDonnell Named to National Academy of Medicine
Duke Cancer Institute
Duke Cancer Institute members Donald P. McDonnell, PhD, and Allan Douglas Kirk, MD, PhD, are among the three Duke faculty members recently named to the National Academy of Medicine, an independent advisory organization made up of leading professionals in health, medicine and the natural, social, and behavioral sciences. Duke's Robert M. Califf, MD, on leave to serve as commissioner of the Food and Drug Administration, was also named. more...
National Organization Honors Prolific Ohio State Scientist, Physician
The Ohio State University Comprehensive Cancer Center
James Cancer Hospital & Solove Research Institute

Maura Gillison, MD, a physician-researcher who has made significant contributions to the fields of cancer biology, therapy and epidemiology, has received one of the country's highest and most prestigious honors in the fields of health and medicine. Dr. Gillison, a member of the cancer control program at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James), was elected a member of the National Academy of Medicine (NAM) during the association's recent annual meeting. more...
Karmanos Named Screening Center of Excellence
Barbara Ann Karmanos Cancer Institute
The Barbara Ann Karmanos Cancer Institute's main campus in Detroit, along with Karmanos' Lawrence and Idell Weisberg Cancer Treatment Center in Farmington Hills, Mich., have been designated a Screening Center of Excellence by the Lung Cancer Alliance (LCA). This designation highlights Karmanos Cancer Institute's ongoing commitment to responsible lung cancer screening. more...
Torres to Hold Glenn Family Chair in Breast Cancer Research
Winship Cancer Institute
Mylin A. Torres, MD, director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University (Winship), was selected to hold the Louisa and Rand Glenn Family Chair in Breast Cancer Research. The endowed position was created by the Wilbur and Hilda Glenn Family Foundation to support the leader of the center and to assist with the further development of Winship's research and clinical efforts in breast cancer. more...
City of Hope Recognized for Patient Care
City of Hope Comprehensive Cancer Center
Press Ganey, the health care industry's leading performance-improvement firm, has honored City of Hope, a world-renowned independent research and cancer treatment center, with two prestigious awards for top-quality inpatient care for the eighth consecutive year. City of Hope earned the Press Ganey Pinnacle of Excellence Award and the Guardian of Excellence Award in Patient Experience, which are both based on inpatient satisfaction surveys. more...
Kachnic Elected President of the American Board of Radiology
Vanderbilt-Ingram Cancer Center
Lisa Kachnic, MD, chair of the Department of Radiation Oncology at Vanderbilt University Medical Center (VUMC), has been elected president of the American Board of Radiology (ABR). She assumed the role after being chosen president-elect of the organization in March 2014 and succeeds former ABR President Milton Guiberteau, MD. Dr. Kachnic officially began her role as president on October 26 at the completion of the fall ABR meeting in California. Over the years, she has served in a volunteer role on many of the organization's oversight committees and has been an elected member of their board since 2010. more...
Heath Honored With Inaugural Michigan Cancer Consortium Champion Award
Barbara Ann Karmanos Cancer Institute
Elisabeth Heath, MD, FACP, leader of the Genitourinary Oncology Multidisciplinary Team and the Patricia C. and E. Jan Hartmann Endowed Chair for Prostate Cancer Research at the Barbara Ann Karmanos Cancer Institute, has been honored with the Michigan Cancer Consortium's inaugural Champion Award for 2016. The Champion Award honors an individual who has demonstrated leadership, excellence, success and impact in the fight against cancer. more...
Salgia Receives Award for Treatment, Research on Lung Cancer
City of Hope Comprehensive Cancer Center
Ravi Salgia, MD, PhD, has been recognized for his decades-long dedication to treating lung cancer patients and researching new therapies. Named after the Greek god of medicine and healing, Dr. Salgia has received the 2016 Asclepius Award from the Bonnie J. Addario Lung Cancer Foundation. The foundation is dedicated to fighting lung cancer and turning it into a manageable, curable disease by 2023. more...
Achilefu Elected to Chemistry, Optical Societies
Siteman Cancer Center
Samuel Achilefu, PhD, a Washington University scientist and inventor at Siteman Cancer Center, has been elected as a fellow to the Royal Society of Chemistry and to The Optical Society. He was elected to the Royal Society of Chemistry for his innovative approach of integrating chemical sciences with engineering, biology and medicine, and for his outstanding leadership to the scientific community. He was elected to The Optical Society for pioneering the development of near-infrared molecular imaging and image-guided surgical resection of cancer, and for exceptional leadership and service to the biomedical optics community. more...
Grants & Gifts
$25.2 Million Awarded for National Clinical Trial for Veterans With Lung Cancer
VCU Massey Cancer Center
VCU Massey Cancer Center physician-researcher Drew Moghanaki, MD, MPH, has been awarded $25.2 million from the Veterans Health Administration to lead a national study on an alternative treatment for lung cancer. Dr. Moghanaki practices as a radiation oncologist at the Hunter Holmes McGuire VA Medical Center, which has an affiliation with Massey for its oncology care. He is co-chairing a lung cancer clinical trial that is expected to open later this year and be conducted at 16 Veterans Affairs medical centers across the country. more...
$4.5 Million Received for Inaugural Breast Cancer Research Award
Siteman Cancer Center
Samuel Achilefu, PhD, a scientist and inventor at Siteman Cancer Center and Washington University in St. Louis, has been recognized as the first recipient of the Breast Cancer Research Program Distinguished Investigator Award, from the U.S. Department of Defense. The award comes with $4.5 million to support his innovative work to use light to activate drugs and the immune system in the body. He is developing the approach as a safer and more effective way to treat breast cancer than currently available chemotherapy drugs. more...
Researchers Receive $2.2 Million Grant to Study HERV Expression in Cancer
GW Cancer Center
George Washington University (GW) researchers received a $2.2 million grant from the National Cancer Institute to uncover why certain cancer types increase whereas others are unchanged or even decrease in those with HIV infection. Douglas Nixon, MD, PhD, is the principal investigator on the grant. He is supported by Eduardo M. Sotomayor, MD, director of the GW Cancer Center, which provided seed funding for this research. more...
Study of Enzyme's Link to Growth of Melanoma, Colorectal Cancer Gets $1.5 Million
VCU Massey Cancer Center
VCU Massey Cancer Center researcher Rong Huang, PhD, was recently awarded a $1.5 million grant from the National Institute of General Medical Sciences to study the structure, regulation and inhibition of a class of proteins that have been previously implicated to be involved in the development of malignant melanoma and colorectal cancer. She hopes the results of the five-year study will eventually lead to her long-term goal of discovery of new, effective cancer therapies. more...
Leadership Transitions
Oncology Surgeon, Physician-Scientist Joins UA Cancer Center as Deputy Director
The University of Arizona Cancer Center
William Cance, MD, has joined the University of Arizona Cancer Center as deputy director and will lead the efforts in Phoenix at the UA Cancer Center at Dignity Health St. Joseph's Hospital and Medical Center. Dr. Cance is a fellowship-trained surgical oncologist who treats patients with complex gastrointestinal and endocrine cancers. He has a particular focus on the diagnosis and treatment of thyroid and parathyroid diseases, including thyroid cancer. more...
Moffitt Hires Co-Leader of Immunology Program
Moffitt Cancer Center
Jose R. Conejo-Garcia, MD, PhD, has joined Moffitt Cancer Center as co-leader of the Immunology Program and chair of the Department of Immunology. Dr. Conejo-Garcia's research aims to understand and target mechanisms of immunosuppression in gynecologic malignancies. Prior to joining Moffitt, Dr. Conejo-Garcia was leader of the Tumor Microenvironment and Metastasis Program and director of Graduate Studies at The Wistar Institute in Philadelphia. more...
Research Highlights
Precision Medicine Test for Breast Cancer Helps Guide Chemotherapy Decisions
University of Michigan Comprehensive Cancer Center
One of the earliest widespread applications of precision medicine in cancer care is helping patients and physicians decide whether chemotherapy is needed, a new study finds. Researchers reviewed a test that assesses the risk of breast cancer recurrence and whether chemotherapy is likely to help lower that risk in women with early stage disease. The test looks at 21 genes known to increase risk of cancer recurrence. The idea is to avoid chemotherapy in women at such low risk that aren't likely to benefit from it and to ensure chemotherapy is recommended for women with higher risk. more...
Promise of Better Targeted Treatments Now Possible in Children's Brain Cancer
Huntsman Cancer Institute
More than 4,000 children and teens are diagnosed with brain cancer each year and the disease kills more children than any other cancer. Researchers at Huntsman Cancer Institute at the University of Utah report they have identified an existing group of drugs that appear to reduce or eliminate a certain subgroup of childhood brain cancers while sparing normal brain tissue. The research was conducted using a new zebrafish animal model system developed by the researchers, which closely resembles an aggressive subtype of pediatric brain tumors. more...
Gene Deletion Allows Cancer Cells to Thrive When Migrating within the Brain
University of Texas MD Anderson Cancer Center
Astronauts survive in space by wearing high-tech space suits. But how do brain cancer cells thrive when they migrate to inhospitable sites within the brain? A study at The University of Texas MD Anderson Cancer Center believes their survival may be due to deficiency of a tumor suppressor gene called quaking, a potential new target for therapies. The study was led by Jian Hu, PhD. more...
Study Shows How Smoking Causes the Changes That Lead to Lung Cancer
University of New Mexico Comprehensive Cancer Center
New research shows that smoking a pack of cigarettes per day for a year causes an average of 150 additional mutations in the DNA of lung cells and causes mutations in the DNA of other cells in the body. This is the first study to show the process by which smoking causes these cancers. The lead co-authors of the paper are: Ludmil Alexandrov, PhD, of the UNM Comprehensive Cancer Center; and Sir Michael Stratton, director of the Wellcome Trust Sanger Institute. more...
Patient With Chemotherapy-Induced Heart Failure First to Receive Stem Cells in Clinical Trial
University of Florida Health Cancer Center
For the first time, University of Florida Health cardiologists have implanted stem cells into the heart of a breast cancer survivor with heart failure in a Phase 1 clinical trial that will examine the feasibility and safety of treating these kinds of patients with stem cells. In the next phases of clinical trials, the researchers will be studying whether stem cells from healthy subjects can improve heart function in patients who have been treated with a group of drugs called anthracyclines, chemotherapy drugs that are still used today. more...
Checkpoint Blockade Helps Only a Subset of Patients, But Why?
The University of Chicago Medicine Comprehensive Cancer Center
Although many cancer patients respond favorably to immunotherapies such as nivolumab and pembrolizumab, most patients do not. Blame for treatment failures is usually attributed to so-called "cold" tumors, those that do not attract T-cell infiltration and may lack key T-cell targets the mutated proteins known as neoantigens. Teams from the University of Chicago (including Thomas Gajewski, MD, PhD, and Jason Luke, MD) and Johns Hopkins University have published a pair of related studies looking at biomarkers involved in the immune system's response to tumors in a recent issue of the Proceedings of the National Academy of Sciences. more...
Outreach to Cirrhosis Patients Doubles Early Screening Rates for Deadly Liver Cancer
Simmons Comprehensive Cancer Center, UT Southwestern Medical Center
Proactive outreach to cirrhosis patients in a safety net health system successfully doubled their screening rates for liver cancer, UT Southwestern Medical Center researchers found. The study randomly divided 1,800 cirrhosis patients at Parkland Health & Hospital System in Dallas into three groups. The first group received mailed outreach invitations for screening ultrasound. The second group received similar outreach plus patient navigation, and the third received their usual care. Researchers learned that the group receiving mailed outreach invitations were most likely to schedule an ultrasound, which doubled the overall rate of screening. more...
Mutant Protein Linked to Spread of Lung Cancer Within the Body
UCSF Helen Diller Family Comprehensive Cancer Center
The ability of lung tumor cells to spread rapidly within the body makes lung cancer difficult to eradicate and contributes to its status as the leading cause of U.S. cancer deaths in both men and women. But according to a new study led by UC San Francisco scientists, the cancer's ability to spread may often be due to the inactivation of a single protective protein within tumor cells. more...
Computer Models Developed to Predict Cancer Cell Network Activity
Case Comprehensive Cancer Center, Case Western Reserve University
A multi-institution academic-industrial partnership of researchers led by Case Western Reserve University School of Medicine has developed a new method to broadly assess cell communication networks and identify disease-specific network anomalies. The computer-based method, called InFlo, was developed in collaboration with researchers at Philips and Princeton University and predicts how cells send signals across networks to cause cancer or other disease. more...
Most Adult Survivors of Childhood Cancer Stop Needed Long-Term Follow-Up Care
Roswell Park Cancer Institute
The first comprehensive study analyzing follow-up care among childhood cancer survivors concludes that fewer than half of the adult survivors of childhood cancers - who remain at greater risk for chronic illnesses - receive adequate long-term follow-up care. The findings of this National Cancer Institute-supported research have been reported by scientists from Roswell Park Cancer Institute. Denise Rokitka, MD, MPH, was the study's lead author. more...
Previously Inaccessible DNA Regions Unlocked, Creating Path for New Drug Discovery
Fox Chase Cancer Center, Temple Health
Researchers at Fox Chase Cancer Center have developed a method of uncovering and studying previously inaccessible DNA, which may enable major advances in research on a number of aggressive cancers. FACT, a highly sought target of cancer drugs, is involved in many cellular processes including gene regulation and cancer development, but the mechanism of its action remained a mystery. Vasily Studitsky, PhD, led a team that discovered a new way for FACT to unspool DNA from the proteins (histones) that normally provide DNA packaging in the small volume of cell nuclei, exposing previously unreachable portions of DNA to interact with other regulatory proteins. Notably, when FACT was removed, the DNA reverted to its natural state with no after-effects. more...
Research Reveals Insight Into Spread of Lung Cancer
University of Texas MD Anderson Cancer Center
A cellular component known as the Golgi apparatus may play a role in how lung cancer metastasizes, according to researchers at The University of Texas MD Anderson Cancer Center. The Golgi apparatus, often referred to as a cellular "post office" for its ability to package proteins into vesicles for transportation to other sites within or outside the cell, may offer a new therapeutic approach for preventing metastasis. more...
Despite Current Practice, Age Should Not Drive Thyroid Cancer Staging
Duke Cancer Institute
A study from the Duke Cancer Institute finds a lack of statistical evidence to support the current practice of treating thyroid cancer patients under age 45 differently from those 45 and older. The study found that in nearly 32,000 cases of papillary thyroid cancer, there was no specific age at which patients' prognoses changed so significantly as to require age-based standards. Julie Ann Sosa, MD, was senior author on the study. more...
Born Rich or Poor? Where You Begin Life Affects Cancer Risk Later
Huntsman Cancer Institute
Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have found that circumstances in childhood, such as parental occupation at birth and neighborhood income, may be associated with different risks of certain cancers later in life. HCI researchers and collaborators at Rutgers University in New Jersey and Temple University Health System in Philadelphia analyzed cancer risk and socioeconomic status of Baby Boomers (for this study, those born during 1945-1959) in two Utah counties. Ken Smith, PhD, was senior author on the study. more...
Less Than Half of Cervical Cancer Patients Receive Standard-of-Care Treatment
University of Colorado Cancer Center
Standard-of-care treatment for locally advanced cervical cancer includes radiation, chemotherapy and brachytherapy (in which radiation is implanted internally). A University of Colorado Cancer Center study published in the journal Gynecologic Oncology shows that only 44 percent of patients in a large, national sample received all three components of this accepted, best treatment. Patients who received standard-of-care (SOC) lived longer than women who received any combination of two components of SOC. The major difference in treatments received and overall survival was the presence or absence of brachytherapy. more...
New Immunotherapy Approach Turns Cells Into "Micro-Pharmacies"
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering researchers have developed a potentially powerful lymphoma treatment using modified immune cells that function as on-site "micro-pharmacies," churning out proteins for therapeutic effect. In experiments with human tumors transplanted into mice, the new immunotherapy approach produced significant responses, raising hopes that this technique could someday offer an effective way of treating this disease and possibly other cancers. more...
Targeted Injectable Chemotherapy Treatment for Dogs Could Lead to Human Trials
University of Kansas Cancer Center
Daniel Aires, MD, researcher at The University of Kansas Cancer Center and director of dermatology at University of Kansas Medical Center, and Laird Forrest, PhD, an associate professor at KU School of Pharmacy, have developed a new injectable chemo treatment for canines, which could lead to testing in humans. In clinical trials, the drug, called HylaPlat, was injected directly into cancerous tumors in dogs, and the researchers say the results have shown great promise in treating a variety of cancers. more...
Repeating DNA Sequences Play a Role in Bone Cancer
UNC Lineberger Comprehensive Cancer Center
Researchers at the University of North Carolina Lineberger Comprehensive Cancer Center report that certain short, repetitive sequences of DNA, or "junk," play an important role in the development of Ewing sarcoma, a rare bone and soft tissue cancer that occurs most commonly in children and adolescents. Ian J. Davis, MD, PhD, is the study’s senior author. more...
Link Shown Between Molecular Mechanisms in Prostate Cancer, Ewing’s Sarcoma
Indiana University Melvin and Bren Simon Cancer Center
Medical researchers at Indiana University Bloomington have found evidence for a link between prostate cancer, which affects millions of men age 50 and older, and Ewing’s sarcoma, a rare form of cancer that affects children and young adults. The results of the study suggest that the molecular mechanism that triggers the rare disease Ewing’s sarcoma could act as a potential new direction for the treatment of more than half of patients with prostate cancer. more...
Could Targeting a Gene Linked to Microcephaly Lead to Better Brain Cancer Treatment?
UNC Lineberger Comprehensive Cancer Center
University of North Carolina Lineberger Comprehensive Cancer Center researchers have identified a potential new treatment for brain cancer by learning from a rare condition that can cause microcephaly. Their study found that genetic deletion of Atr in mice reduced cerebellar growth by causing the death of dividing cells called neural progenitors. These cells are not only important for brain growth, but can also be cells of origin for medulloblastoma. Deleting Atr in transgenic mice prone to developing a specific type of medulloblastoma completely blocked tumor growth, showing that this type of medulloblastoma, like neural progenitors, require ATR to survive. more...
Statewide Lung Cancer Research Initiative Launched With Pelotonia Support
The Ohio State University Comprehensive Cancer Center
James Cancer Hospital & Solove Research Institute

The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) is set to launch a new statewide clinical research initiative with support from Pelotonia. Led by Peter Shields, MD, David Carbone, MD, PhD, and Mary Ellen Wewers, PhD, the study has two aims: to evaluate the impact of advanced gene testing and expert advice on lung cancer treatment and subsequent patient survival; and to improve smoking cessation rates among smokers with lung cancer and their family members. more...
Hopkins Aims to Develop Personalized Approach for Cancer Immunotherapy
Sidney Kimmel Comprehensive Cancer Center
A new five-year collaboration between Johns Hopkins University and biopharmaceutical company Bristol-Myers Squibb aims to determine why some patients being treated for cancer respond to immunotherapy drugs called checkpoint blockers and some do not, and to develop more effective combination immunotherapies. Projects included in the collaboration will span laboratory research on patients' tumor samples and several early-stage clinical trials led by Johns Hopkins scientists at the Bloomberg-Kimmel Institute for Cancer Immunotherapy. more...
Study Details Rare Heart Risk of Certain Cancer Therapies
Vanderbilt-Ingram Cancer Center
Combination therapy using two approved immunotherapy drugs for cancer treatment may cause rare and sometimes fatal cardiac side effects linked to an unexpected immune response. In a study led by Vanderbilt University Medical Center investigators, researchers describe two cases of acute and unexpected fatal myocarditis (inflammation of the heart muscle) that occurred in melanoma patients following treatment with a combination of ipilimumab and nivolumab. more...
New Target Could Halt Growth and Spread of Ovarian Cancer
University of Michigan Comprehensive Cancer Center
Researchers have identified a protein that helps ovarian cancer cells multiply and spread. By blocking it with a new antibody agent, they could slow the cancer's growth and stop it from metastasizing. The finding has potential to lead to a treatment to prevent or limit ovarian cancer in women at high risk. more...
Renal Mass Biopsies May Improve Kidney Cancer Outcomes
Fox Chase Cancer Center, Temple Health
In a single study based on a review of a database assembled over the last 15 years, Fox Chase Cancer Center researchers recently showed that renal mass biopsy enabled accurate diagnosis of renal cell carcinoma. It can also be used to stratify patients based on disease risk — potentially minimizing the risk of over- or under-treatment in groups who could be on surveillance versus those who need surgery because of more aggressive renal tumors. Rosaleen Parsons, MD, FACR, was an author on the study. more...
Long-Sought Genetic Model of Common Infant Leukemia Described
The University of Chicago Medicine Comprehensive Cancer Center
After nearly two decades of unsuccessful attempts, researchers from the University of Chicago Medicine and the Cincinnati Children's Hospital Medical Center have created the first mouse model for the most common form of infant leukemia. Their discovery could hasten development and testing of new drug therapies. more...
Does a Cancer Cell's Shape Hint at its Danger?
University of Colorado Cancer Center
Doctors can sometimes use a cancer cell's genetics to predict how it will act – how dangerous it is and thus what treatments should be used against it. Now a new paper shows that a cancer cell's shape may offer similar clues. Eventually, the researchers from Colorado State University hope that their measurements of cell shape could be combined with genomic data to offer a more precise prognosis and guide strategies for treating a patient's disease. more...
Most Women Unaware of Breast Density's Effect on Cancer Risk, Study Finds
University of Virginia Cancer Center
Most women don't know that having dense breasts increases their risk for breast cancer and reduces a mammogram's ability to detect cancer, according to a University of Virginia School of Medicine study. A random phone survey of 1,024 Virginia women ages 35 to 70, conducted by the UVA Center for Survey Research, found that just 1 in 8 women were aware that breast density is a risk factor for breast cancer, while just 1 in 5 women knew that dense breasts reduced the sensitivity of mammograms to find tumors. more...
Other News
UT Health Science Center San Antonio, MD Anderson Announce Affiliation
Cancer Therapy and Research Center at the University of Texas Health Science Center
The University of Texas Health Science Center at San Antonio and The University of Texas MD Anderson Cancer Center announce an affiliation to create a comprehensive and clinically integrated cancer care program in San Antonio. Beginning in mid-2017, the UT Health San Antonio MD Anderson Cancer Center will provide adult cancer patients in South Texas greater access to the most advanced oncology care available. Through this affiliation, the Cancer Therapy & Research Center (CTRC) of the UT Health Science Center will collaborate as part of MD Anderson's international network of hospitals and health care systems dedicated to ending cancer globally. more...
Moffitt Celebrates 30 Years of Cancer Treatment and Prevention
Moffitt Cancer Center
Moffitt Cancer Center opened its doors in 1986 as the only institution in the nation directly financed on tobacco tax. Today, Moffitt is the 6th-ranked cancer hospital in the nation according to U.S. News and World Report, employs more than 5,200 team members and has an economic impact in the state of $2.1 billion. more...
Broad New Partnership Launches Plan to Reduce Cancer in San Francisco
UCSF Helen Diller Family Comprehensive Cancer Center
Cancer is the leading cause of death in San Francisco and costs patients, families and taxpayers hundreds of millions of dollars each year. Seeing an opportunity to change this, a group that includes UC San Francisco (UCSF), the City and County of San Francisco, the San Francisco Department of Public Health, and health care and community organizations has launched the San Francisco Cancer Initiative (SF CAN), a major public health effort to reduce cancer in San Francisco. SF CAN, conceived and supported by UCSF, aims to reduce the incidence and mortality from the most common cancers in San Francisco that are likely to be affected by known interventions or better screening. more...
Immunology Center Marks 25 Years of Changing Approach to Disease
University of Virginia Cancer Center
In 1991, with financial support from businessman Beirne B. Carter, the University of Virginia established the Beirne Carter Center for Immunology Research. In those days, the notion that there could be a vaccine for cancer would have drawn scoffs. There wasn't even agreement in the scientific community that the human body could have an immune response to cancer. It wasn't an infection, wasn't the result of some bacterium, virus or parasite. So why would the immune system be involved? more...
Job Opportunities
Faculty and Nursing Opportunities  
University of New Mexico Comprehensive Cancer Center
more...

Associate Director of Administration  
Hollings Cancer Center, Medical University of South Carolina
more...

Associate Director of Administration  
University of Hawaii Cancer Center, University of Hawaii at Manoa
more...

Director of Nursing  
UC San Diego Moores Cancer Center
more...
Meeting Announcements

2017 NACCDO/PAMN Annual Conference
2017 NACCDO/PAMN Annual Conference
April 18-21, 2017
Lexington, Kentucky
For more information visit: NACCDO/PAMN

2017 Cancer Center Administrators Forum & CCAF-IT
Hosted by Moffitt Cancer Center
April 30 - May 2, 2017
The Vinoy Renaissance
St. Petersburg, Florida
For more information visit: moffitt.org

9th Annual AACI Clinical Research Initiative Meeting
Save the Date!
July 12-13, 2017
Loews Chicago O'Hare Hotel

2017 AACI/CCAF Annual Meeting
Save the Date!
October 15-17, 2017
Grand Hyatt Washington, DC